近日,生物制药公司Janssen Research&Development宣布,美国FDA已授予其在研抗抑郁新药esketamine突破性疗法认定,适用于有自杀倾向的重度抑郁症(Major depression disorder)。如果最终获得FDA批准,esketamine将是近50年来治疗重度抑郁症的第一个新药。 抑郁症是一种在全世界范围内常见的精神疾患,估计共有3.5亿名患者,遍布各个...
New research based on real‐world data presented at the American Psychiatric Association''s annual meeting May 18–22 in San Francisco found a need to increase and improve interventions to deliver better outcomes for adults with major depressive disorder (MDD) or who have been diagnosed with ...
Originator Janssen Research & Development Developer Janssen Research & Development; Minerva Neurosciences Class Antidepressants; Fluorinated hydrocarbons; Ketones; Pyrimidines; Pyrroles; Sleep disorder therapies; Small molecules; Triazoles Mechanism of Action Orexin receptor type 2 antagonists Orphan Drug ...
今天,生物制药公司 Janssen Research & Development 宣布,美国FDA已授予其在研抗抑郁新药 esketamine 突破性疗法认定,适用于有自杀倾向的重度抑郁症(Major depression disorder)。如果最终获得FDA批准,esketamine 将是近50年来治疗重度抑郁症的第一个新药。 抑...
CRAIG L. TENDLER, M.D. VICE PRESIDENT ONCOLOGY CLINICAL DEVELOPMENT AND GLOBAL MEDICAL AFFAIRS Craig Tendler, M.D. is Vice President, Oncology Clinical Development and Global Medical Affairs at Janssen Research & Development, LLC. In this position, he ... ...
Research & Development Our research pipeline is rich with transformational science reflecting our unique approach to innovation. See More > R&D Data Science Using data science and digital health to reimagine the discovery and development of medicines to advance our mission of bringing transformativ...
近日,生物制药公司Janssen Research & Development 宣布,美国FDA已授予其在研抗抑郁新药esketamine突破性疗法认定,适用于有自杀倾向的重度抑郁症。如果最终获得FDA批准,esketamine 将是近50年来治疗重度抑郁症的第一个新药。 今天,生物制药公司Janssen Research & Development 宣布,美国FDA已授予其在研抗抑郁新药 esketamine...
1 Comment An app designed to help patients remember important medical events was recently released for the iPhone. Care4Today, created by Janssen Research &... Improving the Process of Obtaining Advance Care Plans (ACP) The Connection Between Hospital Readmissions and Post-Acute Care ...
今天,生物制药公司Janssen Research & Development 宣布,美国FDA已授予其在研抗抑郁新药 esketamine 突破性疗法认定,适用于有自杀倾向的重度抑郁症(Major depression disorder)。如果最终获得FDA批准,esketamine 将是近50年来治疗重度抑郁症的第一个新药。 抑郁症是一种在全世界范围内常见的精神疾患,估计共有3.5亿名患者...
证券时报e公司讯,12月7日,金斯瑞生物科技子公司传奇生物宣布,美国食品药品监督管理局(FDA)正式授予Janssen Research&Development,LLC(Janssen)的JNJ-68284528(JNJ-4528)突破性疗法认定(BTD)。这也是该产品今年上半年获得美国FDA孤儿药认证和欧洲药品管理局优先药物认定(PRIME)资格后,再次获得国际权威认可。 (中国证券网)...